Patents by Inventor Kent S. Boles

Kent S. Boles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10584347
    Abstract: The present invention provides recombinant host cells that produce proteins or therapeutic proteins, and nucleic acid constructs for producing the cells. The cells have nucleic acid constructs that encode a heterologous protein, for example an antibody. The nucleic acid constructs also can have a functional signal sequence that directs the secretion of the protein from the cell. The signal sequence can be any functional signal sequence, and various signal sequences are disclosed herein. The invention also provides methods of producing the proteins.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: March 10, 2020
    Assignee: Conagen Inc.
    Inventors: Nicky C. Caiazza, Jun Urano, Maung N. Win, Kent S. Boles
  • Publication number: 20170268015
    Abstract: The present invention provides recombinant host cells that produce proteins or therapeutic proteins, and nucleic acid constructs for producing the cells. The cells have nucleic acid constructs that encode a heterologous protein, for example an antibody. The nucleic acid constructs also can have a functional signal sequence that directs the secretion of the protein from the cell. The signal sequence can be any functional signal sequence, and various signal sequences are disclosed herein. The invention also provides methods of producing the proteins.
    Type: Application
    Filed: March 15, 2017
    Publication date: September 21, 2017
    Inventors: Nicky C. Caiazza, Jun Urano, Maung N. Win, Kent S. Boles
  • Patent number: 7524622
    Abstract: Natural killer (NK) cells possess the inherent capacity to kill various tumor and virally infected cells. A large family of NK cell receptors belongs to the C-type lectin super-family. Genes in the NK gene complex encode type II receptors and examples include the families of NKR-P1, Ly-49, and NKG2 receptors. Examples of other C-type lectin-like receptors that occur as individual genes are CD94, CD69 and AICL. The invention includes a cDNA that encodes a predicted protein of 191 amino acid residues having similarity to the carbohydrate recognition domain of C-type lectins. The predicted protein of LLT1 shows 59 and 56% similarity to AICL and CD69, respectively. A monoclonal antibody (L9.7) against LLT1 receptor was generated. Binding of mAb L9.7 to surface LLT1 induced interferon gamma production in YT, a human NK cell line, as well as in resting and IL-2 activated NK cells, without modulating cytotoxicity.
    Type: Grant
    Filed: April 14, 2005
    Date of Patent: April 28, 2009
    Assignee: University of North Texas Health Science Center at Fort Worth
    Inventors: Porunelloor A. Mathew, Kent S. Boles
  • Publication number: 20040001804
    Abstract: Natural killer (NK) cells constitute the third major population of lymphocytes. They possess the inherent capacity to kill various tumor and virally infected cells and mediate the rejection of bone marrow grafts. A large family of NK cell receptors belong to the C-type lectin family and are localized to NK gene complex on chromosome 6 or 12 in the mouse or human, respectively. Genes in the NK gene complex are all type II receptors and examples include the families of NKR-P1, Ly-49, and NKG2 receptors. Examples of other C-type lectin-like NK cell receptors that occur as individual genes are CD94, CD69, and AICL. Here we report the molecular characterization of a human lectin-like transcript (LLT1) expressed on NK, T, and B cells and localized to the NK gene complex within 100 kb of CD69.
    Type: Application
    Filed: December 31, 2002
    Publication date: January 1, 2004
    Inventors: Porunelloor A. Mathew, Kent S. Boles